Voting is now closed. Thank you for participating and helping us build a great SOCAP14!

MPTs: Impact Investing for Global Reproductive Health

Bethany Young Holt, PhD., CAMI Health, Initiative for Multipurpose Prevention Technologies (IMPT)

Global health relies on the health of women and their families. Today we have 86 million unintended pregnancies around the world every year, 2.7 million new HIV cases, and 1 million people contracting a new sexually transmitted infection (STI) every day. Multipurpose Prevention Technologies (MPTs) deliver comprehensive prevention to enable women to simultaneously protect themselves from unintended pregnancy, HIV and other STIs and their dangerous related consequences. Condoms are the only MPTs that are currently available, but the reality is that millions of women do not use them— only 8% of couples use condoms. We need more comprehensive prevention tools, but the world of family planning, STI and HIV prevention occupy three distinct silos—constituting three distinct sectors for funding, research and development that rarely engage in the same conversations. Join us to learn about an innovative approach being mobilized to innovate new comprehensive sexual and reproductive health prevention products. Learn about MPTs- what products are currently in the pipeline—and how smart high level collaboration strategies are being mobilized to bridge and transcend the barriers to innovation using a Collective Impact Collaboration model to bring together researchers, bio tech developers, funders, scientists, women’s health advocates, behavioral scientists, marketers, industry and agencies together. Collaboration is the most effective path to broad social impact. Working together across sectors, disciplines, funding and research silos and public private divides is the smart and efficient way to share findings and expertise to reduce redundancies and maximize impact. We will share both the innovations in science that are emerging from this collaboration as well as background on the collaboration framework that can be applied to other social impact endeavors to reduce redundancy and more efficiently bring about change.
Collective Impact Collaboration, Health Impact Investing, MPTs, Prevention, Prevention Innovations, Sexual and Reproductive Health
Bethany Young Holt, PHD, CAMI Health, IMPT, and Principle Investigator at PHI (Public Health Institute). Panel facilitator and presenter, Dr. Holt has a broad background in sexual and reproductive health epidemiology and prevention in the US and in Africa, including multi-level analyses, social determinants of health, microbicide acceptability studies, and market research. As the Executive Director of CAMI Health, the coordinator of the international Initiative for Multipurpose Prevention Technologies, Dr. Holt spearheads the multidisciplinary, international teams of researchers, including clinicians, product developers, socio-behavioral and market researchers, fluid mechanical engineers, advocates and community groups to collaborate to develop this new field of sexual and reproductive health products.
Dr. Craig Cohen Craig Cohen, MD, MPH, is a Professor In-Residence in the UCSF Department of Obstetrics, Gynecology and Reproductive Sciences, Co-Director of the UC Global Health Institute (UCGHI) Center of Expertise in Women’s Health & Empowerment, International Director for the UCSF-Gladstone Institute Center for AIDS Research (CFAR) and an Attending Physician at San Francisco General Hospital. He conducts medical research in three major areas: i) HIV and sexually transmitted infection prevention, ii) HIV/AIDS care and support and iii) integration of HIV and reproductive health services in developing countries. Joseph Romano, PhD., is currently President of NWJ Group, LLC, and serves as a consultant to the HIV prevention field. Previously, Dr. Romano was Chief and Executive Director of Product Development for International Partnership for Microbicides (IPM), where he led the development of a number of microbicide products including dapivirine vaginal ring and gel, maraviroc combination products, and other early stage compounds. Before joining IPM, he was Vice President of research at Biosyn, a small biotech company that was focused on women's health products, including microbicides and contraceptives. Prior to this, he worked for 10 years in an AKZO-Nobel subsidiary, Organon-Tekinka, where he was involved in various HIV research and development projects including HIV pathology, immune response characterization, vaccines and diagnostic technology development. Ariane van der Straten, PhD, is a senior research scientist and expert in female-initiated HIV-prevention methods. Dr. van der Straten conducts biomedical and behavioral research for prevention of heterosexual transmission of HIV, with a focus on female-initiated methods, microbicides, and multipurpose prevention technologies. She has led or participated in the development and implementation of major research projects in Africa and the U.S., including Phase I to Phase III trials of the diaphragm and gel, oral and vagina Tenofovir-based pre-exposure prophylaxis, and the vaginal ring. She has also led several studies focusing on adherence-related issues in the context of prevention trials, using quantitative and qualitative research methods.
List of relevant peer reviewed articles: Website for the Initiative for Multipurpose Prevention: “When Condoms Are Not Enough,” Bill and Melinda Gates Impatient Optimist Blog:

Leave a Reply